A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure.

Little is known about costs and cost-effectiveness of liver transplantation (LTx) for acute liver failure compared to costs and cost-effectiveness of LTx for chronic liver failure. In this study, costs of acute and of chronic LTx patients were determined in a retrospective study. Files of 100 consecutive patients who underwent LTx in 1993-1997 were studied. Costs up to 1 year after LTx were Euro 107,675 (chronic liver failure) and Euro 90,792 (acute liver failure). The difference was mainly caused by higher hospitalisation costs and higher personnel costs for chronic liver failure. Medication costs for acute liver failure were higher, due to a high administration rate of expensive anti-HBs immunoglobulin therapy in patients with viral hepatitis B. LTx for chronic liver failure is more costly and seems to be more cost-effective than LTx for acute liver failure, since 1-year survival is higher in patients who underwent transplantation for chronic liver failure.

Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy.

Lamivudine, a novel cytosine analogue, exhibits potent antiviral activity against hepatitis B virus (HBV) in vitro and in vivo. The standard HBV DNA hybridization assay used in phase II clinical studies has a low sensitivity, the detection limit of HBV DNA levels being approximately 10(7) genome equivalents per ml (geq ml-1). In this work we used a semiquantitative polymerase chain reaction (PCR) assay (detection limit approximately 10(3) geq ml-1) to determine HBV DNA levels during a 24-week study of lamivudine in 51 stable chronic hepatitis B patients who were positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Patients were randomly allocated to receive oral doses of 25, 100 or 300 mg lamivudine once daily. At week 24 the median serum concentration of HBV DNA had fallen from 10(8) to 10(4) geq ml-1, a 4-log median reduction. A trend towards more profound suppression of viral replication with an increased dose of lamivudine was observed. After 12 weeks of therapy, 12% of patients had an HBV DNA level that was undetectable in the PCR assay; this increased to 26% after 24 weeks, while in an additional 20% of patients, HBV DNA decreased to the level of detection of the PCR assay. We conclude that a 24-week course of lamivudine decreases serum HBV DNA to the level of PCR detection in 46% of patients. Such additional viral suppressive activity with higher doses and more protracted lamivudine may be of clinical utility prior to liver transplantation. Further studies are needed to define the degree of virus suppression required in clinical practice, and methods are required to increase the efficacy of virus suppression.

[Focal nodular hyperplasia of the liver: assessment of diagnosis and treatment in 31 patients in 15 years]. / Focale nodulaire hyperplasie van de lever: evaluatie van diagnostiek en behandeling bij 31 patiënten in 15 jaar.

OBJECTIVE: Analysis of the diagnostic approach, therapy and management of focal nodular hyperplasia (FNH) of the liver. SETTING: University Hospital Rotterdam-Dijkzigt, Rotterdam. DESIGN: Retrospective follow-up analysis. METHOD: Medical records of patients with histologically proven FNH were analysed with respect to complaints, diagnostic approach and therapeutic management. Follow-up took place at the outpatient clinic where history-taking, physical examination, ultrasonography and hepatitis B and C serology tests were performed. RESULTS: Thirty-one patients with histologically proven focal nodular hyperplasia were treated: 19 were treated conservatively, 12 underwent hepatic resection; one of these patients died postoperatively. Follow-up investigation was carried out in 16 and 9 patients, respectively. Laboratory results did not contribute to the diagnosis. Computed tomography was the most reliable imaging method; 71% of the lesions were correctly diagnosed. After a median follow-up of 52 months none of the patients treated conservatively showed tumour growth on ultrasonography. CONCLUSIONS: The most efficient approach to confirm the diagnosis of focal nodular hyperplasia consists of an ultrasound-guided needle biopsy and histological examination of the specimen. Conservative management is the treatment of choice in focal nodular hyperplasia. Hepatic resection should only be performed in symptomatic patients, in case of tumour growth or of uncertain histological diagnosis, to exclude a malignant process.